Turn precision medicine into action
When you’re driven to improve cancer patients’ lives, turn to a leader in oncology clinical trial development.
Through CerbACT, our immuno-oncology Center of Excellence, we empower precision medicine research by applying deep and wide biomarker expertise, translational research, and clinical development strategy.
From our purpose-built lab facility in Taiwan, CerbACT Asia supports I/O drug developers globally with cutting edge technology in FCM, histopathology, immunohistochemistry, and NGS sequencing, to turn precision medicine into action.
Download our flyer here – https://www.cerbaresearch.com/cerbact-asia-immuno-oncology-center-of-excellence/cerbact__flyer_a4/
Flow Cytometry
Histopathology and immunohistochemistry (IHC)
Peripheral blood mononuclear cell (PBMC) and cell isolations
Genomics Testing
CerbACT is a joint venture between Cerba Research and ACT Genomics, developed to meet the needs of IO drug developers. A synergistic combination of expertise and capabilities to solve precision medicine challenges by advancing your research with a new platform combining deep scientific expertise and technical capabilities:
For biotech, pharmaceutical, government, and non-government organizations, CerbACT turns precision medicine innovation into action.
Explore the CerbACT Asia Laboratory
Watch the below video for a glimpse at our facility in Taipei, and a short overview of the instruments and technology present to support you in your Immuno-oncology research.